Home/Pipeline/LAPS GLP-1/GLP-2 Dual Agonist

LAPS GLP-1/GLP-2 Dual Agonist

Gastrointestinal Diseases

PreclinicalActive

Key Facts

Indication
Gastrointestinal Diseases
Phase
Preclinical
Status
Active
Company

About Zealand Pharma

Zealand Pharma's mission is to develop transformative peptide-based medicines that address the root causes of metabolic and gastrointestinal diseases, aiming to increase healthspan rather than merely treat symptoms. The company has achieved significant validation through strategic partnerships with major pharmaceutical players and has built a robust clinical pipeline anchored by its dual and triple agonists for obesity. Its strategy combines internal R&D excellence with selective collaborations to accelerate development and maximize global commercial reach.

View full company profile

Other Gastrointestinal Diseases Drugs

DrugCompanyPhase
G-test Portfolio ExpansionGenloxaDevelopment